Skip to NavigationSkip to content

Clinigen shares soar after $210m Novartis cancer drug deal

Published on 13/02/19 at 09:49am

British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal worth $210 million.

Clinigen, a growing speciality pharma group, already sells Proleukin outside of the US. Proleukin is used to treat metastatic kidney cancer and metastatic melanoma.

Clinigen will pay an initial sum of $120 million for the US rights alongside a further $60 million which will be differed for a year. The remaining $30 million will be paid dependent on the drug reaching certain sales milestones.

Proleukin generated $60 million in US sales last year. Clinigen believe the drug could become an integral component of cancer combination therapies.    

“This highly earnings enhancing acquisition of US rights to Proleukin is significant to the whole group not just the commercial medicines division,” said chief executive Shaun Chilton.

Shares in the firm were up by nearly 15% on announcement of the news.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches